Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement ease long COVID? small study hints at hope

NCT ID NCT06974058

Symptom relief Sponsor: Liaquat University of Medical & Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a dietary supplement containing quercetin and curcumin in 15 adults with mild to moderate Long COVID symptoms like fatigue, brain fog, and body pain. Participants took two capsules twice daily for 8 weeks. The goal was to see if the supplement could reduce overall symptom burden and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
quercetin and curcumin dietary supplement
What this could lead to
If it works, this could point toward a simple, over-the-counter supplement to help manage lingering Long COVID symptoms like fatigue and pain.
What could go wrong
This was a very small study with only 15 people and no placebo group, so results may not be reliable or apply to everyone. Supplements are not strictly regulated, so quality and effects can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jul 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18 to 75 years. * History of confirmed COVID-19 infection at least 6 months prior to the enrollment. * Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection. * Diagnosis of Long COVID-19 based on WHO criteria. * Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). * At least one symptom scoring between 1-7 on the C19-YRS. * Stable medical condition: No recent hospitalization (past 3 months) due to acute illness. * Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation Exclusion Criteria: * Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®). * Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease). * Regular use of quercetin or curcumin supplements within the last 3 months. * Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin. * Acute illness at the time of screening. * Pregnancy or breastfeeding. * Use of immunosuppressive medications or corticosteroids within the past month. * Significant psychiatric disorder that may interfere with study compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID

Contacts and locations

Locations

  • Liaquat University of Medical & Health Sciences (LUMHS)

    Jamshoro, Sindh, 76090, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.